Printer Friendly Printed from http://www.researchandmarkets.com/reports/835 Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old Regimens Description: The pharmacological treatment of lung cancer has been dominated by the platinum analogs for over a decade and with no immediate replacements in sight, they are expected to play a core role in ling cancer management for the foreseeable future. However, this is not to say that the lung cancer market will stagnate over the next seven years. With the emergence of innovative, lower toxicity agents, treatment outcomes for patients with lung cancer look set to improve dramatically. With new treatments poised to take the market by storm. Drugs of Tomorrow 2000: Lung Cancer provides a detailed examination of the current lung cancer pipeline activities in 7 major pharmaceutical markets, together with in-depth analysis of the most promising classes and drugs in development to 2007 enabling you to competitively position your products, strengthen your marketing strategy and market penetration, expose potential threats to your business and target R&D resources more effectively. Contents: Introduction to Datamonitor About Healthcare TABLE OF CONTENTS EXECUTIVE SUMMARY Report summary Introduction Patient potential in lung cancer Unmet needs in lung cancer Investors in lung cancer Class focus Future market leaders R&D opportunities in lung cancer DISEASE OVERVIEW Definition of lung cancer NSCLC SCLC Classification of lung cancer Disease type Staging for lung cancer Performance status Age at diagnosis Prognostic factors Classification of pipeline products Cytotoxic therapies: an overview Alkylating agents Antimetabolites Vinka alkaloids Other cytotoxics Angiogenesis inhibitors Immunotherapies Gene therapies Clinical endpoints in lung cancer Survival Toxicity Quality of life Response rates Multiple end points Unmet needs in lung cancer Extended disease-free survival Reduced toxicity Metastatic disease Second line therapy Older patients Screening Prevention LUNG CANCER PIPELINE ANALYSIS Pipeline analysis by development strategy Key drug discovery strategies in lung cancer Key R&D protocol strategies in lung cancer Key drug delivery strategies in lung cancer Key licensing strategies in lung cancer Pipeline analysis by class Pipeline analysis by region Pipeline analysis by company type Pipeline analysis by individual company DRUG ANALYSIS Cytotoxics Multitargeted antifolate (Alimta) Tirazone (tirapazamine) SPI-77 Troxacitabine Pivanex DA-125 XR5000 CP 358,774 Decitabine ILX-295501 DX-8951f Irofulven (MGI-114) Angiogenesis inhibitors Neovastat Prinomastat Marimastat SU5416 Iressa Immunotherapies Mitumomab rhuMAb-VEGF SRL 172 Recombinant interferon beta BLP25 Gene therapies ISIS 3521 SCH 58500 RPR/INGN 201 Genasense Others RSR13 Incel (biricodar) Key phase I development projects Research developments TheraFab NC381 Recently discontinued projects BMS 182751 BAY 12 9566 COMPARATIVE ANALYSIS Comparison by class Survival Toxicity Elderly patients Refractory/relapsed disease Marketing strength Comparative analysis of cytotoxics Comparison of disease-free survival in cytotoxics Comparison of toxicity in cytotoxics Comparison of cytotoxics in elderly patients Comparison of cytotoxics in refractory/relapsed disease Comparison of marketing strength in cytotoxics Comparative analysis of antiangiogenic agents Comparison of disease-free survival in antiangiogenic agents Comparison of toxicity in antiangiogenic agents Comparison of performance of antiangiogenic in elderly patients Comparison of antiangiogenic agents in refractory/relapsed disease Comparison of marketing strength in antiangiogenic agents Comparative analysis of immunotherapies Comparison of disease-free survival in immunotherapies Comparison of toxicity in immunotherapies Comparison of immunotherapies in elderly patients Comparison of immunotherapies in refractory/relapsed disease Comparison of marketing strength in immunotherapies FUTURE FOCUS IN LUNG CANCER Future trends in the incidence and prevalence of lung cancer Prospective drug launches in lung cancer Launch forecast methodology Forecast launches in lung cancer from 2000 to 2007 Market forecasts, 2000-2007 Forecast methodology Lung cancer market forecast, 2000-2007 Lung cancer drug class forecast, 2000- 2007 Key R&D product forecasts APPENDIX Clinical trial data bibliography Forecasting drug launches Global highest stage of development Reclassification of development phases List of tables List of figures Ordering: Order Online - visit http://www.researchandmarkets.com/reports/835 Order by Fax - using the order form below Order By Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland. Page 1 of 2 Printed 30/08/2008 15:46:57 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com Order information Please verify that the product information is correct and select the format you require. Product Name: Drugs of Tomorrow 2000: Lung Cancer - New Partners For Old Regimens Web Address: http://www.researchandmarkets.com/reports/835 Office Code: OCHGMLLTRSX Report formats Please enter the quantity of the report format you require. Format Quantity Price Hard Copy €6,591.00 + EUR€ 50.00 Shipping/Handling * Electronic €6,527.00 Electronic - Site License €6,527.00 * Shipping/Handling is only charged once per order. Contact information Please enter all the information below in BLOCK CAPITALS. First Name:   Last Name:   Email Address: Job Title: Organisation: Address: City: Postal/Zip Code: Country: Phone Number: Fax Number: Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World Page 2 of 2 Printed 30/08/2008 15:46:57 Payment information Please indicate the payment method you would like to use by selecting the appropriate box.  Pay by Credit Card: American Express Diners Club Master Card Visa Cardholder Name: Expiry Date: / Card Number: CVV Security Code: Issue Date: /   (Diners Club only)  Pay by Check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.  Pay by Wire Transfer: Please transfer funds to: Account number: 83313083 Sort code: 98-53-30 Swift code: ULSBIE2D IBAN number: IE78ULSB98533083313083 Bank Address: Ulster Bank, 27-35 Main St, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp Please fax this form to: (646)607-1907 or (646)964-6609 - From USA +353-1-481-1716 or +353-1-653-1571 - From Rest of World